NASDAQ:ARDX - Ardelyx Stock Price, Price Target & More

$4.90 -0.17 (-3.35 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$4.90
Today's Range$4.85 - $5.15
52-Week Range$4.05 - $14.10
Volume434,674 shs
Average Volume305,395 shs
Market Capitalization$268.96 million
P/E Ratio-3.60
Dividend YieldN/A
Beta0.79

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Debt-to-Equity RatioN/A
Current Ratio8.38%
Quick Ratio8.38%

Price-To-Earnings

Trailing P/E Ratio-3.60
Forward P/E Ratio-2.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$42 million
Price / Sales5.55
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book1.67

Profitability

EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-44.48%
Return on Assets-39.42%

Miscellaneous

Employees75
Outstanding Shares47,600,000

How to Become a New Pot Stock Millionaire

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx (NASDAQ:ARDX) released its quarterly earnings results on Wednesday, March, 14th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.60. The biopharmaceutical company had revenue of $42 million for the quarter, compared to analyst estimates of $6 million. View Ardelyx's Earnings History.

What price target have analysts set for ARDX?

6 analysts have issued 1 year target prices for Ardelyx's shares. Their predictions range from $12.00 to $17.00. On average, they anticipate Ardelyx's share price to reach $13.6667 in the next twelve months. View Analyst Ratings for Ardelyx.

What are Wall Street analysts saying about Ardelyx stock?

Here are some recent quotes from research analysts about Ardelyx stock:
  • 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (3/20/2018)
  • 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
  • Dr. Reginald Seeto, COO & Exec. VP (Age 46)
  • Dr. Paul Korner, Chief Medical Officer & Exec. VP (Age 52)
  • Mr. Mark E. Kaufmann MBA, CFO & Treasurer (Age 50)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)

Has Ardelyx been receiving favorable news coverage?

News articles about ARDX stock have trended somewhat positive recently, according to Accern. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ardelyx earned a news sentiment score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $4.90.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $268.96 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (ARDX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ardelyx (NASDAQ:ARDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Ardelyx in the last 12 months. Their average twelve-month price target is $13.6667, suggesting that the stock has a possible upside of 178.91%. The high price target for ARDX is $17.00 and the low price target for ARDX is $12.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.6667$13.6667$13.6667$16.40
Price Target Upside: 178.91% upside155.45% upside91.14% upside156.25% upside

Ardelyx (NASDAQ:ARDX) Consensus Price Target History

Price Target History for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Leerink SwannReiterated RatingOutperform -> Outperform$13.00MediumView Rating Details
3/17/2018Cantor FitzgeraldSet Price TargetBuy$12.00MediumView Rating Details
3/15/2018WedbushReiterated RatingOutperformMediumView Rating Details
11/29/2017CitigroupBoost Price TargetBuy -> Buy$16.00 -> $17.00LowView Rating Details
11/22/2017Ladenburg ThalmannLower Price TargetBuy -> Buy$19.00 -> $16.00N/AView Rating Details
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 -> $12.00HighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Ardelyx (NASDAQ:ARDX) Earnings History and Estimates Chart

Earnings by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.44)($0.20)($0.32)
Q2 20182($0.48)($0.21)($0.35)
Q3 20182($0.51)($0.23)($0.37)
Q4 20182($0.47)($0.24)($0.36)

Ardelyx (NASDAQ ARDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018Q4 2017($0.39)$0.21$6.00 million$42.00 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.54)($0.44)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.63)($0.54)ViewListenView Earnings Details
5/5/2017Q1 2017($0.6520)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.6570)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.0150)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ardelyx (NASDAQ:ARDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ardelyx (NASDAQ ARDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.47%
Institutional Ownership Percentage: 74.26%
Insider Trading History for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ ARDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2017Reginald SeetoCOOSell10,008$5.20$52,041.60View SEC Filing  
8/30/2017Forest BaskettMajor ShareholderSell485$4.95$2,400.75View SEC Filing  
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.0022,144View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.001,440View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.0047,420View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.0047,420View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.0025,880View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.4025,880View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.0047,420View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.651,518View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.8625,880View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ardelyx (NASDAQ ARDX) News Headlines

Source:
DateHeadline
BidaskClub Upgrades Ardelyx (ARDX) to "Hold"BidaskClub Upgrades Ardelyx (ARDX) to "Hold"
www.americanbankingnews.com - April 19 at 11:03 AM
Ardelyx (ARDX) Forecasted to Earn Q1 2018 Earnings of ($0.44) Per ShareArdelyx (ARDX) Forecasted to Earn Q1 2018 Earnings of ($0.44) Per Share
www.americanbankingnews.com - April 18 at 7:58 AM
FY2021 Earnings Estimate for Ardelyx (ARDX) Issued By Leerink SwannFY2021 Earnings Estimate for Ardelyx (ARDX) Issued By Leerink Swann
www.americanbankingnews.com - April 17 at 7:07 AM
Ardelyx (ARDX) Given Average Recommendation of "Hold" by AnalystsArdelyx (ARDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 5:45 AM
Comparing Syndax Pharmaceuticals (SNDX) and Ardelyx (ARDX)Comparing Syndax Pharmaceuticals (SNDX) and Ardelyx (ARDX)
www.americanbankingnews.com - April 11 at 3:32 AM
Ardelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald AnalystsArdelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 11 at 12:43 AM
-$0.40 EPS Expected for Ardelyx (ARDX) This Quarter-$0.40 EPS Expected for Ardelyx (ARDX) This Quarter
www.americanbankingnews.com - April 10 at 3:10 AM
Ardelyx (ARDX) Downgraded by ValuEngine to Strong SellArdelyx (ARDX) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 8:45 PM
 Analysts Expect Ardelyx Inc (ARDX) to Announce -$0.40 Earnings Per Share Analysts Expect Ardelyx Inc (ARDX) to Announce -$0.40 Earnings Per Share
www.americanbankingnews.com - March 24 at 3:21 AM
Cantor Fitzgerald Research Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)Cantor Fitzgerald Research Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)
www.americanbankingnews.com - March 23 at 10:56 AM
Ardelyx Inc to Post Q1 2018 Earnings of ($0.40) Per Share, Leerink Swann Forecasts (ARDX)Ardelyx Inc to Post Q1 2018 Earnings of ($0.40) Per Share, Leerink Swann Forecasts (ARDX)
www.americanbankingnews.com - March 21 at 7:20 AM
Ardelyx Inc (ARDX) Receives Average Recommendation of "Hold" from AnalystsArdelyx Inc (ARDX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 5:36 AM
Ardelyx (ARDX) Downgraded by Zacks Investment Research to SellArdelyx (ARDX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 20 at 5:56 PM
Ardelyx (ARDX) Now Covered by Analysts at Leerink SwannArdelyx (ARDX) Now Covered by Analysts at Leerink Swann
www.americanbankingnews.com - March 19 at 10:46 AM
Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in CanadaArdelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
finance.yahoo.com - March 19 at 10:00 AM
Ardelyx Inc (ARDX) Forecasted to Post FY2021 Earnings of $0.70 Per ShareArdelyx Inc (ARDX) Forecasted to Post FY2021 Earnings of $0.70 Per Share
www.americanbankingnews.com - March 19 at 9:48 AM
Ardelyxs (ARDX) Outperform Rating Reaffirmed at WedbushArdelyx's (ARDX) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 18 at 5:38 PM
BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21
www.reuters.com - March 16 at 10:03 AM
Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of DirectorsArdelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
finance.yahoo.com - March 14 at 4:41 PM
Ardelyx posts 4Q profitArdelyx posts 4Q profit
finance.yahoo.com - March 14 at 4:41 PM
Ardelyx Inc (ARDX) Receives Consensus Rating of "Hold" from AnalystsArdelyx Inc (ARDX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 5:36 AM
Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 18 at 3:32 PM
Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)
www.americanbankingnews.com - February 12 at 1:32 PM
Ardelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.comArdelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.com
www.streetinsider.com - February 12 at 6:37 AM
Ardelyx Announces Departure of Chief Scientific OfficerArdelyx Announces Departure of Chief Scientific Officer
finance.yahoo.com - February 12 at 6:37 AM
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceArdelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:24 PM
Ardelyx (ARDX) Downgraded by BidaskClubArdelyx (ARDX) Downgraded by BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Ardelyx (ARDX) Cut to Hold at Zacks Investment ResearchArdelyx (ARDX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 2 at 5:36 PM
Ardelyx (ARDX) Stock Rating Upgraded by Zacks Investment ResearchArdelyx (ARDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 5:56 PM
Ardelyx Inc (ARDX) Given Average Recommendation of "Buy" by BrokeragesArdelyx Inc (ARDX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 30 at 8:18 AM
Ardelyx (ARDX) Stock Rating Upgraded by BidaskClubArdelyx (ARDX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 27 at 4:28 PM
Ardelyx (ARDX) Downgraded by Zacks Investment Research to HoldArdelyx (ARDX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 23 at 6:44 PM
Ardelyx (ARDX) Stock Rating Lowered by BidaskClubArdelyx (ARDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 21 at 4:58 PM
Stock Review for Biotechs Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)Stock Review for Biotech's Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:08 AM
BRIEF-Ardelyx Says Co Had About $134 Million In CashBRIEF-Ardelyx Says Co Had About $134 Million In Cash
www.reuters.com - January 8 at 8:56 AM
Ardelyx Inc (ARDX) Receives Consensus Rating of "Buy" from BrokeragesArdelyx Inc (ARDX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 8:28 AM
Can The Uptrend Continue for Ardelyx (ARDX)?Can The Uptrend Continue for Ardelyx (ARDX)?
finance.yahoo.com - January 4 at 11:03 AM
Ardelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.comArdelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.com
www.streetinsider.com - January 3 at 3:50 PM
BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-CBRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
www.reuters.com - January 3 at 10:38 AM
Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
finance.yahoo.com - January 3 at 10:38 AM
January Growth Stock OpportunitiesJanuary Growth Stock Opportunities
finance.yahoo.com - January 1 at 3:50 PM
Why Ardelyx (ARDX) Could Beat Earnings Estimates Again - NasdaqWhy Ardelyx (ARDX) Could Beat Earnings Estimates Again - Nasdaq
www.nasdaq.com - December 27 at 11:49 AM
Reviewing KemPharm (KMPH) and Ardelyx (ARDX)Reviewing KemPharm (KMPH) and Ardelyx (ARDX)
www.americanbankingnews.com - December 26 at 11:54 PM
Why Ardelyx (ARDX) Could Beat Earnings Estimates AgainWhy Ardelyx (ARDX) Could Beat Earnings Estimates Again
finance.yahoo.com - December 26 at 12:19 PM
Ardelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China - StreetInsider.comArdelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China - StreetInsider.com
www.streetinsider.com - December 12 at 11:50 AM
BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in ChinaBRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
www.reuters.com - December 11 at 11:51 AM
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in ChinaArdelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
finance.yahoo.com - December 11 at 11:51 AM
Ardelyx, Inc. (ARDX) Given Consensus Recommendation of "Buy" by AnalystsArdelyx, Inc. (ARDX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 5:56 AM
Ardelyx, Inc. Expected to Earn FY2017 Earnings of ($1.88) Per Share (ARDX)Ardelyx, Inc. Expected to Earn FY2017 Earnings of ($1.88) Per Share (ARDX)
www.americanbankingnews.com - December 1 at 11:07 AM
Ardelyx (ARDX): PT To $17 After Partnering with KHK in Japan - Citi - StreetInsider.comArdelyx (ARDX): PT To $17 After Partnering with KHK in Japan - Citi - StreetInsider.com
www.streetinsider.com - November 30 at 3:48 PM

SEC Filings

Ardelyx (NASDAQ:ARDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ardelyx (NASDAQ:ARDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ardelyx (NASDAQ ARDX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.